(AP) -- By now, millions of anthrax vaccine shots developed through cutting-edge genetic engineering were supposed to be filling a new national stockpile of biodefense drugs. Instead, five years after anthrax attacks left five dead, sickened 17 and panicked the country, the nearly $1 billion contract awarded by the U.S. Department of Health and Human Services to a tiny and struggling San Francisco Bay Area biotechnology company is plagued with misfortune and delays.
Content from The Associated Press expires 15 days after original publication date. For more information about The Associated Press, please visit www.ap.org .
Explore further: Acne pill benefits outweigh blood clot risk: EU agency